The goal of this program is to improve treatment of acute myeloid leukemia (AML). After hearing and assimilating this program, the clinician will be better able to:
1. Cite the advancements and challenges of venetoclax therapy.
2. Implement strategies for prevention and monitoring of tumor lysis syndrome.
3. Differentiate between various types and generations of FLT3 inhibitors.
4. Optimize use of new treatments such as anti-CD47 antibody.
5. Recommend specific treatment strategies to target IDH mutations.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Oncology
- Start Date: 2022-05-04 05:00:00
- End Date: 2022-05-04 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.75 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest